Navigation Links
Elekta / Mitsubishi Electric Collaboration Helps Japan's Gunma University Heavy Ion Medical Center Launch Advanced Carbon Ion Therapy for Treating Cancer
Date:5/17/2010

flexibility to integrate state-of-the-art planning capabilities across a wide range of radiation therapy delivery techniques."

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology
2. Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity
3. CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM)
4. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
5. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
6. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
7. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
8. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
9. Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC
10. Elekta Negotiates To Acquire CMS
11. Elekta Showcases Stereotactic Systems for Cancer Care at Astro 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
... relatively spherical objects in a sauce blueberries in ... of completely encapsulated berries. Relying on that concept, ... in protective coatings in the belief such encapsulations would ... Unfortunately, reactions in the nanoworld are not logical extensions ...
... On October 10, the web domain "GenerationHealth.com" was listed for auction ... expected to deliver a price reminiscent of the early dot-com days. ... expected to garner a lot of attention due to the fact ... frequently lately for various reasons, and also because the domain can ...
... AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures Corporation ... Editorial Board of Standard and Poor,s ("S&P") has ... Market Access Program. Standard & Poor,s Corporation Records ... U.S. and international public companies by investors and ...
Cached Biology Technology:Nanoscopic particles resist full encapsulation, Sandia simulations show 2Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Bacteria that can cause serious heart disease in humans are ... could become a bigger problem in humans. Research published in ... suggests that brown rats, the biggest and most common ... Since the early 1990s, more than 20 species of ...
... kills pain by activating a set of proteins ... appetite, inflammation, and memory. The body also has ... same receptors, namely N-arachidonoyl ethanolamine (AEA) and 2-arachidonoylglycerol ... remain the focus of intense efforts to develop ...
... Nov. 21 Futronic Technology Company Limited, a,global ... the,commercial release of FS22, a high performance fingerprint ... its previously launched,FS21M (mid-range device) and FS20 (low ... fingerprint access and attendance control device.,FS22 uses a ...
Cached Biology News:Scientists discover 21st century plague 2Scripps research team defines new painkilling chemical pathway 2Futronic Launches FS22 Fingerprint Access Control Device 2